List of insiders holdings for Chemomab Therapeutics Ltd.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| THIEL PETER 10% Owner | 2021-03-26 08:10:07 | 22,631,260 0 | 22,631,260 | Form 13G |
| Access Industries Holdings LLC Clal Biotechnology Industries Ltd. ACCESS INDUSTRIES LLC ACCESS INDUSTRIES MANAGEMENT LLC Blavatnik Len 10% Owner | 2021-04-15 17:28:03 | 5,057,766 0 | 5,057,766 | Form 13D |
| Gabriel Capital Management Ltd. 10% Owner | 2022-02-10 16:02:58 | 3,087,040 0 | 3,087,040 | Form 13G |
| Haluska Frank Chief Executive Officer | 2020-01-02 16:33:58 | 2,148,236 0 | 2,148,236 | Form 3 |
| OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership 10% Owner | 2024-09-16 16:34:03 | 1,860,906 0 | 1,860,906 | Form 13D |
| Mor George Adi Chief Scientific Officer | 2024-11-29 15:04:59 | 898,221 0 | 898,221 | Form 13D |
| Pfost Dale R Chief Executive Officer | 2022-03-15 16:10:10 | 461,853 0 | 461,853 | Form 4 |
| VERU DENNISON T Director | 2020-01-02 16:34:21 | 81,900 369,640 | 451,540 | Form 3 |
| Burgin Jonathan See Remarks | 2020-01-02 16:34:45 | 340,037 0 | 340,037 | Form 3 |
| Kerstein David Chief Medical Officer | 2020-01-02 16:31:04 | 340,000 0 | 340,000 | Form 3 |
| Fatal Sigal Chief Financial Officer | 2023-06-16 16:03:05 | 273,669 0 | 273,669 | Form 4 |
| Knickerbocker Ron See Remarks | 2020-01-02 16:32:13 | 235,000 0 | 235,000 | Form 3 |
| Marvin Donald Executive VP, CFO & COO | 2022-06-21 06:01:38 | 198,875 0 | 198,875 | Form 4 |
| SQUINTO STEPHEN P Director | 2021-04-21 17:16:57 | 168,624 0 | 168,624 | Form 4 |
| Frankel Matthew Bejosa Chief Medical Officer | 2022-11-15 16:03:38 | 125,000 0 | 125,000 | Form 3 |
| Gilon Ohev-Zion Michal VP, Research and Development | 2020-01-02 16:33:35 | 100,254 0 | 100,254 | Form 3 |
| Daly Sean T VP, Clinical Operations | 2020-01-02 16:32:44 | 80,000 0 | 80,000 | Form 3 |
| Aharon Arnon Chief Medical Officer | 2021-03-25 10:11:21 | 75,232 0 | 75,232 | Form 3 |
| HOWARD LAWRENCE Director | 2020-01-02 16:30:40 | 55,000 15,385 | 70,385 | Form 3 |
| Darvish Nissim Director | 2023-07-05 17:48:43 | 57,456 0 | 57,456 | Form 4 |
| Alon Ruth Director | 2020-01-02 16:35:08 | 55,353 0 | 55,353 | Form 3 |
| Makov Efrat Director | 2020-01-02 16:31:25 | 55,353 0 | 55,353 | Form 3 |
| Polovets Stanislav Director | 2021-03-12 16:28:05 | 55,000 0 | 55,000 | Form 4 |
| HARDY REGINALD L Director | 2020-01-02 16:35:30 | 55,000 0 | 55,000 | Form 3 |
| Kohlberg Isaac T. Director | 2020-01-02 16:31:51 | 55,000 0 | 55,000 | Form 3 |
| Cohen Neil Harris Director | 2023-03-23 07:35:31 | 36,267 0 | 36,267 | Form 4 |
| Quigley Jill M. Director | 2023-06-20 06:03:03 | 34,137 0 | 34,137 | Form 4 |
| Roshan Salar Head of Business Development | 2020-01-02 16:33:06 | 30,000 0 | 30,000 | Form 3 |
| Nicaise Claude Director | 2023-03-23 07:36:58 | 25,561 0 | 25,561 | Form 4 |
| Moses Alan Charles Director | 2023-03-23 07:38:42 | 25,561 0 | 25,561 | Form 4 |
| Maryles Joel Michael Director | 2022-05-25 16:03:50 | 20,137 0 | 20,137 | Form 4 |
| Fine Andrew Chief Financial Officer | 2021-03-11 18:34:09 | 0 0 | 0 | Form 3 |
| DiPalma Stephen J. Chief Financial Officer | 2020-05-07 16:16:21 | 0 0 | 0 | Form 3 |
| Gonen Ofer Director | 2020-01-02 17:08:41 | 0 0 | 0 | Form 3 |